Navigation Links
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.
Date:3/6/2013

NEW YORK, March 6, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Impax Laboratories Inc. ("Impax" or the "Company") (NasdaqGS: IPXL). The investigation focuses on whether the Company and its executives violated federal securities laws.

On March 4, 2013, Shares of Impax dropped $4.10, or 20.5 percent, to $15.90 in aftermarket trading following the Company's announcement that the FDA issued a new Form 483 with twelve observations, three of which are designated as repeat observations from past inspections. New and pending applications that relate to the Hayward, California manufacturing facility may be withheld by the FDA until the Form 483 problems are solved. The FDA sent Impax a warning letter in January 2011 based on an inspection of the Hayward, Calif., plant, and found other problems in a March 2012 inspection. The March 2012 inspection, the FDA said the original problems had been addressed, but it found problems in its quality control laboratory. Shares of Impax stock were down over 25% in early trading on March 5, 2013 from its prior days close. 

If you are aware of any facts relating to this investigation, or purchased shares of Impax, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email eitan@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman , 212-697-6484
eitan@bgandg.com


'/>"/>
SOURCE Bronstein, Gewirtz & Grossman, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alexza Pharmaceuticals Inc.
2. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
3. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
4. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
5. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
6. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
11. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, September 18 ... D.C. offering free MRI brain scans to the public.Where:  ... be parked at 501 K Street NW, Washington, D.C.What:BTF brings its nationwide ...
(Date:9/9/2017)... INDIANAPOLIS , Sept. 9, 2017  Eli Lilly ... key primary and secondary endpoint data for lasmiditan, an ... migraine, which demonstrated statistically significant improvements compared to placebo ... be highlighted today at the 18th Congress of the ... . "The data presented today demonstrate lasmiditan,s ...
(Date:9/7/2017)... , Sept. 7, 2017  For nearly two decades, New Life ... the Assisted Reproduction Insurance industry. Today, New Life Agency announces a powerful ... ... (PRNewsfoto/PharmaCareCard) ... http://pharmacarecard.com/ ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... ... communities, nine governmental public health departments have been awarded five-year accreditation status through ... that the benefits of being served by a PHAB-accredited health department now ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... ... using Microscan’s LVS 7510 at the Global GS1 Healthcare Conference 2017 in Chicago, ... the life-sciences industry for ensuring label quality and improving patient safety. , ...
(Date:9/21/2017)... ... 2017 , ... Japanese Zen artist couple, Fumie and Kentaro Mune, have announced ... October at Miranda Kuo Gallery on Lower East Side, NYC. This exhibition will feature ... Wanderlust , one of the largest US yoga online media outlets in the ...
(Date:9/21/2017)... ... September 21, 2017 , ... Sagora Senior Living, one ... at Kingwood Assisted Living and Memory Care located at 24025 Kingwood Place Drive, ... assisted living apartments, 43 memory care apartments and 23 extended care apartments. Modern ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... center in Prescott, Arizona, is now accredited by The Joint Commission for chemical ... organization that accredits and certifies U.S. health care organizations that meet the commission’s ...
Breaking Medicine News(10 mins):